MAGEB2 is Activated by Promoter Demethylation in Head and Neck Squamous Cell Carcinoma

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Pattani, Kavita M ^a   Soudry, Ethan ^a   Glazer, Chad A ^a   Ochs, Michael F ^a   Wang, Hao ^a   Schussel, Juliana ^a   Sun, Wenyue ^a   Hennessey, Patrick ^a   Mydlarz, Wojciech ^a   Loyo, Myriam ^a   Demokan, Semra ^a,b   Smith, Ian M ^a   Califano, Joseph A ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b ISTANBUL UNIVERSITY   (Turkey)

^c GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; KERATINOCYTE; MAGEB2 GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; UPREGULATION;

ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; TRANSCRIPTIONAL ACTIVATION;

EID: 84866648093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045534     Document Type: Article

References (34)

1. Brieger J, Pongsapich W, Mann SA, Hedrich J, Fruth K, et al. (2010) Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma. Oral Oncol 46: 678-683.
2. Glazer CA, Smith IM, Ochs MF, Begum S, Westra W, et al. (2009) Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS One 4: e8189.
3. Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, et al. (2009) Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 4: e4961.
4. Sun W, Liu Y, Glazer CA, Shao C, Bhan S, et al. (2010) TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res 16: 857-866.
5. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010.
6. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, et al. (2002) Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2: 485-495.
7. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
8. Li LC, Dahiya R, (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431.
9. Calmon MF, Colombo J, Carvalho F, Souza FP, Filho JF, et al. (2007) Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer. Cancer Genet Cytogenet 173: 31-37.
10. Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, et al. (2006) Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res 66: 9401-9407.
11. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, et al. (2008) Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 14: 97-107.
12. Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, et al. (2010) Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 70: 2870-2879.
13. Chen K, Sawhney R, Khan M, Benninger MS, Hou Z, et al. (2007) Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 133: 1131-1138.
14. Demokan S, Chang X, Chuang A, Mydlarz WK, Kaur J, et al. (2010) KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. Int J Cancer 127: 2351-2359.
15. Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, et al. (2003) Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res 9: 3635-3640.
16. Ha PK, Califano JA, (2006) Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7: 77-82.
17. Loyo M, Brait M, Kim MS, Ostrow KL, Jie CC, et al. (2011) A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer.
18. Paluszczak J, Krajka-Kuzniak V, Malecka Z, Jarmuz M, Kostrzewska-Poczekaj M, et al. (2011) Frequent gene hypermethylation in laryngeal cancer cell lines and the resistance to demethylation induction by plant polyphenols. Toxicol In Vitro 25: 213-221.
19. Pattani KM, Zhang Z, Demokan S, Glazer C, Loyo M, et al. (2010) Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) 3: 1093-1103.
20. Righini CA, de Fraipont F, Timsit JF, Faure C, Brambilla E, et al. (2007) Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res 13: 1179-1185.
21. Sharma R, Panda NK, Khullar M, (2010) Hypermethylation of carcinogen metabolism genes, CYP1A1, CYP2A13 and GSTM1 genes in head and neck cancer. Oral Dis 16: 668-673.
22. Yalniz Z, Demokan S, Suoglu Y, Ulusan M, Dalay N, (2011) Simultaneous methylation profiling of tumor suppressor genes in head and neck cancer. DNA Cell Biol 30: 17-24.
23. Lurquin C, De Smet C, Brasseur F, Muscatelli F, Martelange V, et al. (1997) Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. Genomics 46: 397-408.
24. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T, (1999) DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19: 7327-7335.
25. Jang SJ, Soria JC, Wang L, Hassan KA, Morice RC, et al. (2001) Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 61: 7959-7963.
26. Nagashima H, Sadanaga N, Mashino K, Yamashita K, Inoue H, et al. (2001) Expression of MAGE-B genes in esophageal squamous cell carcinoma. Jpn J Cancer Res 92: 167-173.
27. Rawlins EL, Hogan BL, (2006) Epithelial stem cells of the lung: privileged few or opportunities for many? Development 133: 2455-2465.
28. Caballero OL, Chen YT, (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100: 2014-2021.
29. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ, (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625.
30. Laduron S, Deplus R, Zhou S, Kholmanskikh O, Godelaine D, et al. (2004) MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 32: 4340-4350.
31. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, et al. (2006) MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 103: 11160-11165.
32. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, et al. (2010) Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 95: 785-793.
33. Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y, et al. (2007) MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 67: 9954-9962.
34. Marcar L, Maclaine NJ, Hupp TR, Meek DW, (2010) Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 70: 10362-10370.